logo
Surgeon and Professor Is Deported to Lebanon Despite a Judge's Order

Surgeon and Professor Is Deported to Lebanon Despite a Judge's Order

New York Times16-03-2025
A kidney transplant specialist and professor at Brown University's medical school has been deported from the United States, even though she had a valid visa and a court order temporarily blocking her expulsion, according to her lawyer and court papers.
Dr. Rasha Alawieh, 34, a Lebanese citizen who had traveled to Lebanon last month to visit relatives, was detained on Thursday when she returned to the United States, according to a court complaint filed by her cousin Yara Chehab.
Judge Leo T. Sorokin of the Federal District Court in Massachusetts ordered the government on Friday evening to provide the court with 48 hours' notice before deporting Dr. Alawieh. But she was put on a flight to Paris, presumably on her way to Lebanon.
In a second order filed Sunday morning, the judge said there was reason to believe U.S. Customs and Border Protection had willfully disobeyed his previous order to give the court notice before expelling the doctor. He said he had followed 'common practice in this district as it has been for years,' and ordered the federal agency to respond to what he called 'serious allegations.'
A hearing in the case is scheduled for Monday.
Court documents related to the case were provided to The New York Times by Clare Saunders, a member of the legal team representing Ms. Chehab, who filed petitions to prevent her cousin's deportation, and then to request that her cousin be allowed to return to the United States.
Ms. Chehab's petitions name several members of the Trump administration as defendants, including Homeland Security Secretary Kristi Noem, Secretary of State Marco Rubio and the acting commissioner of Customs and Border Protection, Peter Flores.
Thomas Brown, a lawyer representing Dr. Alawieh and her employer, Brown Medicine, said that while the doctor was in Lebanon, the U.S. consulate issued her an H-1B visa, which allows highly skilled foreign citizens to live and work in the United States. Brown Medicine, a nonprofit medical practice, had sponsored her application for the visa.
According to Ms. Chehab's complaint, when Dr. Alawieh landed at Boston Logan International Airport on Thursday, she was detained by Customs and Border Protection officers and held at the airport for 36 hours, for reasons that are unclear.
Ms. Saunders said in an affidavit that she went to the airport Friday and notified Customs and Border Protection officials there — before the flight to Paris was scheduled to depart — that there was a court order barring the doctor's expulsion. She said that the officers there took no action and gave her no information until after the plane had taken off.
The agency did not immediately respond to a request for comment.
Dr. Alawieh graduated from the American University of Beirut in 2015. Three years later, she came to the United States, where she held medical fellowships at the Ohio State University and the University of Washington, and then worked as a resident at Yale.
Before the new visa was issued, she held a J-1 visa, the type commonly used by foreign students.
There is a shortage of American doctors working in Dr. Alawieh's area of specialty: organ transplants. The field is known for grueling, unpredictable work hours, with doctors often flying through the night to pick up donated organs before performing emergency surgery.
'It's very disruptive to family life,' said Dr. David Weill, a former director of Stanford's lung transplant program who is now a consultant to hospitals. Because many younger American physicians have growing concerns about work-life balance, 'a lot of hospitals are turning to talented doctors from outside the U.S. to get this work done,' Dr. Weill said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Warren man charged with possessing child sexually abusive material
Warren man charged with possessing child sexually abusive material

CBS News

timean hour ago

  • CBS News

Warren man charged with possessing child sexually abusive material

A 61-year-old Warren, Michigan, man is accused of possessing and sharing multiple images of child sexually abusive material, the Macomb County Prosecutor's Office said Friday. Michael Cristini is charged with three counts of aggravated possession of child sexually abusive material, three counts of possession of child sexually abusive material and six counts of using a computer to commit a crime, court records show. He was arraigned on Friday at the 37th District Court in Warren. The prosecutor's office alleges that Cristini possessed and shared the child sexually abusive material around May 6. His bond is set at $500,000 cash or surety, according to court records. If released, Cristini won't be able to use the internet or a computer, can't have weapons, drugs or alcohol and will be required to wear a GPS tether. "The charges brought today represent some of the most serious offenses under the law involving the exploitation of children," Macomb County Prosecutor Peter J. Lucido said in a news release on Friday. A probable cause conference for Cristini is scheduled for Aug. 15, followed by a preliminary exam on Aug. 21. If you know of a child who may have been a victim of exploitation, call the National Center for Missing or Exploited Children at 1-800-843-5678 or visit the website.

Americans' becoming more aware of GLP-1 drugs like Ozempic, Wegovy: Survey
Americans' becoming more aware of GLP-1 drugs like Ozempic, Wegovy: Survey

The Hill

time5 hours ago

  • The Hill

Americans' becoming more aware of GLP-1 drugs like Ozempic, Wegovy: Survey

The number of U.S. adults that are aware of GLP-1 drugs used for weight loss, such as Ozempic and Wegovy, has jumped significantly in the last few years, a new survey shows. The YouGov poll, released Friday, shows that at least 80 percent of respondents have heard at least 'a little bit' about semaglutide, a medication used to treat Type 2 diabetes that also helps a user to shed weight. In March 2023, only 60 percent of Americans were aware of the drug. A year later, in March 2024, that number had jumped to 70 percent, the pollster noted. The latest survey also shows that the share of those who have heard 'a lot' about the medication has nearly doubled since 2023, increasing to 41 percent from 23 percent. Just 36 percent of respondents say they know someone who has taken semaglutide. Around 14 percent listed a family member took the medicine, 16 percent named a friend, 11 percent identified an acquaintance and 7 percent said they had taken it themselves, according to the poll. Several also noted they knew a user in more than one category. Women are more likely than men, 43 percent to 29 percent, to know someone — including themselves — who has taken a GLP-1 agonist drug, per the survey. The weight loss medications — including Wegovy, Ozempic, Zepbound and others — have been available since 2005 but have only in the past few years been used to treat obesity. The drugs work by mimicking a hormone in the body — glucagon-like peptide-1 — that stimulates insulin secretion and reduces appetite. Possible side effects of taking the medication include nausea, diarrhea, vomiting, and constipation. While semaglutide is currently only prescribed for weight loss or treating diabetes, early research is pointing to possible benefits for a host of other issues, including treatment for addiction, neurodegenerative diseases and conditions that affect the heart, kidney or liver. The latest survey found that roughly a quarter of respondents said they would be 'very' or 'somewhat' interested in taking the medication as a weight loss treatment. About a third of Americans have either taken the drug or said they would be interested in trying it. On the other side, about 17 percent said they were 'not very' interested in the medication and 45 percent signaled they were not at all interested. A separate poll from last September found that around a quarter of adults in the U.S. would consider using weight loss medications without consulting their doctor. The YouGov analysis is based on an online survey conducted from May 22-25 among 1,109 adults in the U.S. The margin of error for the full sample is 4 percentage points.

Citi Remains Bullish on Sana Biotechnology (SANA)
Citi Remains Bullish on Sana Biotechnology (SANA)

Yahoo

time14 hours ago

  • Yahoo

Citi Remains Bullish on Sana Biotechnology (SANA)

Sana Biotechnology, Inc. (NASDAQ:SANA) is one of the best biotech penny stocks to buy right now. Citi analyst Samantha Semenkow maintained a bullish stance on Sana Biotechnology, Inc. (NASDAQ:SANA), giving it a Buy rating on July 2 with a $15 price target. A scientist working with a microscope in a laboratory, focusing on a cell of a medical experiment. The analyst based the rating on Sana Biotechnology, Inc.'s (NASDAQ:SANA) potential in addressing notable market opportunities. Semenkow stated that the company's Type 1 Diabetes (T1D) program has exhibited considerable proof-of-concept results, with updated six-month data showing durable c-peptide production and successful graft survival without the need for immunosuppression. According to the analyst, this data consistency bolsters confidence in Sana Biotechnology, Inc.'s (NASDAQ:SANA) approach and paints a positive picture for its T1D asset, SC451, anticipated to make progress towards an IND as early as 2026. The same day, Morgan Stanley analyst Maxwell Skor also assumed coverage of Sana Biotechnology, Inc. (NASDAQ:SANA) with an Overweight rating and $12 price target. The analyst expects an investigational new drug filing as early as next year for its proprietary HIP-modified, islet stem-cell derived T1D therapy, SC451. Sana Biotechnology (NASDAQ:SANA) is a biotechnology company that specializes in using engineered cells as medicines. It develops cell engineering programs that transform treatment across several therapeutic areas with treatment gaps, including diabetes, oncology, the central nervous system, and B-cell-mediated autoimmune disorders. While we acknowledge the potential of SANA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store